Detection and localization of early- and late-stage cancers using platelet RNA
Sjors G. J. G. In ‘t Veld(Amsterdam Neuroscience), Mohammad Arkani(Amsterdam Neuroscience), Edward P. Post(Amsterdam Neuroscience), Mafalda Antunes‐Ferreira(Amsterdam Neuroscience), Silvia D’Ambrosi(Amsterdam University Medical Centers), Daan C.L. Vessies(The Netherlands Cancer Institute), Lisa Vermunt(Amsterdam Neuroscience), Adrienne Vancura(Amsterdam Neuroscience), Mirte Muller(The Netherlands Cancer Institute), Anna-Larissa N. Niemeijer(Amsterdam University Medical Centers), Jihane Tannous(Harvard University), Laura L. Meijer(Amsterdam Neuroscience), Tessa Y. S. Le Large(Amsterdam Neuroscience), Giulia Mantini(Amsterdam Neuroscience), Niels E. Wondergem(Amsterdam Neuroscience), Kimberley M. Heinhuis(The Netherlands Cancer Institute), Sandra van Wilpe(Radboud University Nijmegen), J. Smits(Amsterdam University Medical Centers), Esther E.E. Drees(Amsterdam Neuroscience), Eva Roos(Amsterdam University Medical Centers), Cyra E Leurs(Amsterdam Neuroscience), Lee-Ann Tjon Kon Fat(Umeå University), Ewoud J. van der Lelij(Amsterdam Neuroscience), Govert Dwarshuis(Amsterdam Neuroscience), Maarten J. Kamphuis(Amsterdam Neuroscience), Lisanne E. Visser(Amsterdam Neuroscience), Romée Harting(Amsterdam Neuroscience), Annemijn Gregory(Amsterdam Neuroscience), Markus Schweiger(Harvard University), Laurine E. Wedekind(Amsterdam Neuroscience), Jip Ramaker(Amsterdam Neuroscience), Kenn Zwaan(Amsterdam Neuroscience), Heleen Verschueren(Amsterdam Neuroscience), Idris Bahce(Amsterdam University Medical Centers), Adrianus J. de Langen(The Netherlands Cancer Institute), Egbert F. Smit(The Netherlands Cancer Institute), Michel M. van den Heuvel(Radboud University Nijmegen), Koen J. Hartemink(The Netherlands Cancer Institute), Marijke J. E. Kuijpers(Maastricht University Medical Centre), Mirjam G.A. oude Egbrink(Maastricht University), Arjan W. Griffioen(Amsterdam Neuroscience), Rafael Rossel(Instituto Oncológico Dr. Rosell), T. Jeroen N. Hiltermann(University Medical Center Groningen), Elizabeth Lee-Lewandrowski(Harvard University), Kent Lewandrowski(Harvard University), Philip C. De Witt Hamer(Amsterdam Neuroscience), Mathilde C.M. Kouwenhoven(Amsterdam Neuroscience), Jaap C. Reijneveld(Amsterdam University Medical Centers), William P. J. Leenders(Radboud University Nijmegen), Ann Hoeben(Maastricht University), Irma M. Verdonck‐de Leeuw(Amsterdam University Medical Centers), C. René Leemans(Amsterdam University Medical Centers), Robert J. Baatenburg de Jong(Erasmus MC Cancer Institute), Chris H.J. Terhaard(University Medical Center Utrecht), Robert P. Takes(Radboud University Nijmegen), Johannes A. Langendijk(University Medical Center Groningen), Saskia C.A. de Jager(University Medical Center Utrecht), Adriaan O. Kraaijeveld(Utrecht University), Gerard Pasterkamp(University Medical Center Utrecht), Minke Smits(Radboud University Nijmegen), Jack A. Schalken(Radboud University Nijmegen), Sylwia Łapińska‐Szumczyk(Gdańsk Medical University), Anna Łojkowska(Gdańsk Medical University), Anna J. Żaczek(Gdańsk Medical University), Henk M. Lokhorst(Amsterdam Neuroscience), Niels W.C.J. van de Donk(Amsterdam Neuroscience), Inger S. Nijhof(Amsterdam Neuroscience), Henk‐Jan Prins(Amsterdam Neuroscience), Josée M. Zijlstra(Amsterdam Neuroscience), Sander Idema(Amsterdam Neuroscience), Johannes C. Baayen(Amsterdam Neuroscience), Charlotte E. Teunissen(Amsterdam Neuroscience), Joep Killestein(Amsterdam Neuroscience), Marc G. Besselink(Amsterdam University Medical Centers), Lindsay Brammen(Medical University of Vienna), Thomas Bachleitner‐Hofmann(Medical University of Vienna), Farrah J. Mateen(Harvard University), John Th. M. Plukker(University Medical Center Groningen), Michal Heger(Erasmus MC), Quirijn de Mast(Radboud University Nijmegen), Ton Lisman(University Medical Center Groningen), D. Michiel Pegtel(Amsterdam Neuroscience), Harm Jan Bogaard(Amsterdam University Medical Centers), Jacek Jassem(Gdańsk Medical University), Anna Supernat(Gdańsk Medical University), Niven Mehra(Radboud University Nijmegen), Winald R. Gerritsen(Radboud University Nijmegen), Cor D. de Kroon(Leiden University Medical Center), Christianne Lok(The Netherlands Cancer Institute), Jurgen M.J. Piek(Radboud University Nijmegen), Neeltje Steeghs(The Netherlands Cancer Institute), Winan J. van Houdt(The Netherlands Cancer Institute), Ruud H. Brakenhoff(Amsterdam Neuroscience), Gabe S. Sonke(The Netherlands Cancer Institute), Henk M.W. Verheul(Radboud University Nijmegen), Elisa Giovannetti(Fondazione Pisa), Geert Kazemier(Amsterdam Neuroscience), Siamack Sabrkhany(Maastricht University), Ed Schuuring(University Medical Center Groningen), Erik A. Sistermans(Amsterdam University Medical Centers), Rob M.F. Wolthuis(Amsterdam University Medical Centers), Hanne Meijers‐Heijboer(Amsterdam University Medical Centers), Josephine C. Dorsman(Amsterdam University Medical Centers), Cees B.M. Oudejans(Amsterdam University Medical Centers), Bauke Ylstra(Amsterdam Neuroscience), Bart A. Westerman(Amsterdam Neuroscience), Daan van den Broek(The Netherlands Cancer Institute), Danijela Koppers‐Lalic(Amsterdam Neuroscience), Pieter Wesseling(University Medical Center Utrecht), R. Jonas A. Nilsson(Umeå University), W. Peter Vandertop(Amsterdam Neuroscience), David P. Noske(Amsterdam Neuroscience), Bakhos A. Tannous(Harvard University), Nik Sol(Amsterdam Neuroscience), Myron G. Best(Amsterdam Neuroscience), Thomas Würdinger(Amsterdam Neuroscience)
Cited by 122Open Access
Abstract
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.
Related Papers
No related papers found
Powered by citation graph analysis